Desloratadine Fluoxetine

CBrN 506-68-3) see Anagrelide hydrochloride Desloratadine Epinastine hydrochloride Fluoxetine Nalorphine Naloxone Pergolide cyanogen chloride... 

Co-administration of desloratadine with fluoxetine did not result in clinically relevant changes in the pharmacokinetics of either drug in 54 healthy volunteers (19). 

Gupta S, Banfield C, Kantesaria B, Flannery B, Herron J. Pharmacokinetics/pharmacodynamics of desloratadine and fluoxetine in healthy volunteers. J Clin Pharmacol 2004 44(ll) 1252-9. 

The concurrent use of desloratadine 5 mg daily and fluoxetine 20 mg daily for 7 days (after attainment of fluoxetine steady-state) had no clinically relevant effects on the pharmacokinetics of desloratadine or fluoxetine (changes in maximum levels and AUC were less than 15%). There was no change in ECG parameters including the QTc interval, and the combination did not increase the incidence of adverse effects. This study was placebo-controlled and in healthy subjects who were of extensive metaboliser phenotype for CYP2D6. 

The interaction between the SSRIs and terfenadine is not adequately established, and there is little evidence regarding interactions between the SSRIs and astemizole, although it is possible that the contraindication with astemizole has contributed to minimal usage of the combination and therefore a lack of reported interactions. In addition to fluoxetine and paroxetine, the manufacturers of terfenadine list fluvoxamine and citalo-pram as drugs that are expected to increase terfenadine serum levels, but direct evidence of this seems to be lacking. Nonetheless, the manufacturer contraindicates the use of all these SSRIs with terfenadine. Due to the severity of the potential interaction, it would appear prudent to use caution if terfenadine is used with any SSRI (excepting perhaps sertraline), and consider an alternative antihistamine without cardiac effects (see Table 15.2 , (p.583)), wherever possible. Desloratadine appears to be a non-interacting alternative. 

---